Parkinson's disease
Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 525 East 68th Street, A-501, New York, NY 10021, USA
* To whom correspondence should be addressed. Tel: +1 2127465341; Fax: +1 2127468276; Email: bot2003{at}med.cornell.edu
Received May 30, 2007; Revised May 30, 2007; Accepted June 20, 2007
Parkinson's disease (PD) is a chronic progressive neurodegenerative movement disorder characterized by a profound and selective loss of nigrostriatal dopaminergic neurons. Clinical manifestations of this complex disease include motor impairments involving resting tremor, bradykinesia, postural instability, gait difficulty and rigidity. Current medications only provide symptomatic relief and fail to halt the death of dopaminergic neurons. A major hurdle in development of neuroprotective therapies are due to limited understanding of disease processes leading to death of dopaminergic neurons. While the etiology of dopaminergic neuronal demise is elusive, a combination of genetic susceptibilities and environmental factors seems to play a critical role. The majority of PD cases are sporadic however, the discovery of genes linked to rare familial forms of disease (encoding 
-synuclein, parkin, DJ-1, PINK-1 and LRRK2) and studies from experimental animal models has provided crucial insights into molecular mechanisms in disease pathogenesis and identified probable targets for therapeutic intervention. Recent findings implicate mitochondrial dysfunction, oxidative damage, abnormal protein accumulation and protein phosphorylation as key molecular mechanisms compromising dopamine neuronal function and survival as the underlying cause of pathogenesis in both sporadic and familial PD. In this review we provide an overview of the most relevant findings made by the PD research community in the last year and discuss how these significant findings improved our understanding of events leading to nigrostriatal dopaminergic degeneration, and identification of potential cell survival pathways that could serve as targets for neuroprotective therapies in preventing this disabling neurological illness.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C.-H. Ng, S. Z. S. Mok, C. Koh, X. Ouyang, M. L. Fivaz, E.-K. Tan, V. L. Dawson, T. M. Dawson, F. Yu, and K.-L. Lim Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila J. Neurosci., September 9, 2009; 29(36): 11257 - 11262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Opherk, M. Duering, N. Peters, A. Karpinska, S. Rosner, E. Schneider, B. Bader, A. Giese, and M. Dichgans CADASIL mutations enhance spontaneous multimerization of NOTCH3 Hum. Mol. Genet., August 1, 2009; 18(15): 2761 - 2767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Simunovic, M. Yi, Y. Wang, L. Macey, L. T. Brown, A. M. Krichevsky, S. L. Andersen, R. M. Stephens, F. M. Benes, and K. C. Sonntag Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology Brain, July 1, 2009; 132(7): 1795 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Lesage, C Condroyer, A Lannuzel, E Lohmann, A Troiano, F Tison, P Damier, S Thobois, A-M Ouvrard-Hernandez, S Rivaud-Pechoux, et al. Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease J. Med. Genet., July 1, 2009; 46(7): 458 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rubio de la Torre, B. Luzon-Toro, I. Forte-Lago, A. Minguez-Castellanos, I. Ferrer, and S. Hilfiker Combined kinase inhibition modulates parkin inactivation Hum. Mol. Genet., March 1, 2009; 18(5): 809 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-H. Lu, S. M. Fleming, B. Meurers, L. C. Ackerson, F. Mortazavi, V. Lo, D. Hernandez, D. Sulzer, G. R. Jackson, N. T. Maidment, et al. Bacterial Artificial Chromosome Transgenic Mice Expressing a Truncated Mutant Parkin Exhibit Age-Dependent Hypokinetic Motor Deficits, Dopaminergic Neuron Degeneration, and Accumulation of Proteinase K-Resistant {alpha}-Synuclein J. Neurosci., February 18, 2009; 29(7): 1962 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Winner, D. M. Vogt-Weisenhorn, C. D. Lie, I. Blumcke, and J. Winkler Review: Cellular repair strategies in Parkinson's disease Therapeutic Advances in Neurological Disorders, January 1, 2009; 2(1): 51 - 60. [Abstract] [PDF]
|
|
|
|
 |
|
 T. D. Helton, T. Otsuka, M.-C. Lee, Y. Mu, and M. D. Ehlers Pruning and loss of excitatory synapses by the parkin ubiquitin ligase PNAS, December 9, 2008; 105(49): 19492 - 19497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Arnold, G. W. de Araujo, and C. Beyer Gender-specific regulation of mitochondrial fusion and fission gene transcription and viability of cortical astrocytes by steroid hormones J. Mol. Endocrinol., November 1, 2008; 41(5): 289 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Zhong and J. Xu Synergistic activation of the human MnSOD promoter by DJ-1 and PGC-1{alpha}: regulation by SUMOylation and oxidation Hum. Mol. Genet., November 1, 2008; 17(21): 3357 - 3367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. McFarland, C. E. Ellis, S. P. Markey, and R. L. Nussbaum Proteomics Analysis Identifies Phosphorylation-dependent {alpha}-Synuclein Protein Interactions Mol. Cell. Proteomics, November 1, 2008; 7(11): 2123 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Marin, W. N. van Egmond, and P. J. M. van Haastert The Roco protein family: a functional perspective FASEB J, September 1, 2008; 22(9): 3103 - 3110. [Abstract] [Full Text] [PDF]
|
|